{"groups":[{"description":"Parameningeal (without intracranial extension) and paraspinal tumors receive chemotherapy starting Week 1 and begin radiation therapy at Week 20. Weeks 1-6: vincristine sulfate and irinotecan hydrochloride. Weeks 7-34: vincristine sulfate and irinotecan hydrochloride, Cyclophosphamide with MESNA, Doxorubicin hydrochloride, Etoposide, Ifosfamide with MESNA. Weeks 35-54: vincristine sulfate, Dactinomycin, irinotecan hydrochloride and Cyclophosphamide with MESNA and Filgrastim. Radiation therapy beginning at Week 20. Second look conventional surgery: Surgical resection other than biopsy will be applicable for the majority of patients.","id":"FG000","title":"High_Risk_Rhabdomyosarcoma"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"11"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"11"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"14"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"109"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"67"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"42"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}